Loading...

Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors

Non-Hodgkin lymphomas comprise a heterogenous group of disorders which differ in biology. Although response rates are high in some groups, relapsed disease can be difficult to treat, and newer approaches are needed for this patient population. It is increasingly apparent that the immune system plays...

Full description

Saved in:
Bibliographic Details
Published in:J Immunol Res
Main Authors: Joshi, Maansi, Ansell, Stephen M.
Format: Artigo
Language:Inglês
Published: Hindawi 2020
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7690999/
https://ncbi.nlm.nih.gov/pubmed/33294467
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/8820377
Tags: Add Tag
No Tags, Be the first to tag this record!